TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8258031

Group type: EXPERIMENTAL
Intervention: Oral zinc acetate supplementation (600 mg/day) in addition to standard therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Only standard therapy (a diet containing 0.8 g/kg/day of protein and 90 g/day of lactulose)
Number of subjects: 90
Study: 3899084

Group type: EXPERIMENTAL
Intervention: Plain DTP vaccine
Number of subjects: 1075

Group type: COMPARATOR
Intervention: Adsorbed DTP vaccine
Number of subjects: 1075
Study: 30218818

Group type: EXPERIMENTAL
Intervention: Patient Centered Kidney Transition Care (multi-component health system intervention)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Usual nephrology care
Number of subjects: 8
Study: 27455166

Group type: EXPERIMENTAL
Intervention: Antibiotics for a minimum of 5 days, stopped if body temperature was 37.8°C or less for 48 hours and no more than 1 CAP-associated sign of clinical instability.
Number of subjects: 312

Group type: COMPARATOR
Intervention: Control group treatment duration determined by physicians.
Number of subjects: 312
Study: 24981366

Group type: EXPERIMENTAL
Intervention: Immediate cord clamping (within 20 seconds)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Deferred cord clamping (after at least two minutes)
Number of subjects: 100
Study: 22079732

Group type: EXPERIMENTAL
Intervention: Beta-carotene (50 mg on alternate days)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383
Study: 20542799

Group type: EXPERIMENTAL
Intervention: TiNOX coated stents
Number of subjects: 92
Study: 18417275

Group type: EXPERIMENTAL
Intervention: Cetrorelix 5mg/week for 4 weeks
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Cetrorelix 10mg every 2 weeks for 2 doses
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Cetrorelix 10mg/week for 4 weeks
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 15973822

Group type: EXPERIMENTAL
Intervention: Ariston pHc (n=50, without enamel etching and rubber dam)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Solitaire I (n=49, with total etching and rubber dam)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Overall comparison of both materials
Number of subjects: 31

Group type: COMPARATOR
Intervention: Marginal analysis for both materials
Number of subjects: 31
Study: 12829912

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 119

Group type: COMPARATOR
Intervention: CsA-ME
Number of subjects: 119
Study: 11003411

Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced FLASH images
Number of subjects: 36

Group type: COMPARATOR
Intervention: Precontrast spin-echo (SE) and FLASH images
Number of subjects: 36
Study: 9162304

Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber, high-vegetable and -fruit dietary pattern (20% of total energy intake, 18 g/1000 kcal, 5-8 servings daily)
Number of subjects: 2079

Group type: COMPARATOR
Intervention: Control group (standard dietary pattern)
Number of subjects: 2079
Study: 8185335

Group type: EXPERIMENTAL
Intervention: HCFU (long-term administration after radical treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (radical treatment only)
Number of subjects: 0
Study: 3241278

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium restriction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (diuretic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enalapril (ACE inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of nifedipine and enalapril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of nifedipine with sodium restriction or hydrochlorothiazide
Number of subjects: 0
Study: 31780129

Group type: EXPERIMENTAL
Intervention: Overall physical activity
Number of subjects: 91905

Group type: EXPERIMENTAL
Intervention: Sedentary, moderate intensity activity, sleep duration
Number of subjects: 91905
Study: 29404979

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation (HFX) of 72.0 Gy in 60 fractions given twice daily
Number of subjects: 694

Group type: COMPARATOR
Intervention: Standard radiation of 60.0 Gy in 30 fractions given once daily
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation (HFX)
Number of subjects: 694

Group type: COMPARATOR
Intervention: Standard radiation
Number of subjects: 694
Study: 28802594

Group type: EXPERIMENTAL
Intervention: 15mg ketorolac
Number of subjects: 50

Group type: COMPARATOR
Intervention: 30mg ketorolac
Number of subjects: 50
Study: 27089126

Group type: EXPERIMENTAL
Intervention: Natural history data from the FAM study
Number of subjects: 226
Study: 24749259

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trimeperidine
Number of subjects: 0
Study: 21087332

Group type: EXPERIMENTAL
Intervention: PVI plus generalized CFAE ablation
Number of subjects: 80

Group type: COMPARATOR
Intervention: PVI plus selective CFAE ablation targeting only CEA regions
Number of subjects: 80
Study: 19751084

Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy with hypnosis plus education
Number of subjects: 124

Group type: COMPARATOR
Intervention: Education-only control condition
Number of subjects: 124
Study: 17273833

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 0.5% (15 mg)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Hyperbaric prilocaine 2% (60 mg)
Number of subjects: 88
Study: 14745746

Group type: EXPERIMENTAL
Intervention: Hormone therapy (anastrozole, tamoxifen alone or combined)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (women without breast cancer)
Number of subjects: 129
Study: 11501357

Group type: EXPERIMENTAL
Intervention: SIS application around the gastrojejunostomy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no SIS application)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: SIS application
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14
Study: 9632872

Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum at 14 mmHg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Pneumoperitoneum at 10 mmHg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Nonhepatobiliary laparoscopic procedures at 14 mmHg
Number of subjects: 52
Study: 8554360

Group type: EXPERIMENTAL
Intervention: Nebulised amiloride
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (standard inpatient treatment)
Number of subjects: 27
Study: 2528578

Group type: EXPERIMENTAL
Intervention: Isradipine (7.5 mg twice daily)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 329522

Group type: EXPERIMENTAL
Intervention: Sisomicin administered twice daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Gentamicin administered three times daily
Number of subjects: 100
Study: 31705465

Group type: EXPERIMENTAL
Intervention: Patient-family agenda setting checklist
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Various approaches to foster shared decision-making
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Challenges in communication
Number of subjects: 8
Study: 31132222

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (LCZ696) eligibility based on EMA/FDA label
Number of subjects: 5443

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (LCZ696) eligibility based on PARADIGM‐HF trial
Number of subjects: 5443

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (LCZ696) eligibility based on ESC guidelines
Number of subjects: 5443

Group type: EXPERIMENTAL
Intervention: Registry eligible patients
Number of subjects: 5443

Group type: COMPARATOR
Intervention: Enalapril (control group from PARADIGM‐HF)
Number of subjects: 5443
Study: 28618286

Group type: EXPERIMENTAL
Intervention: Insomnia severity
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Symptoms of depression
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Symptoms of PTSD
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Symptoms of depression and PTSD
Number of subjects: 622
Study: 26081053

Group type: EXPERIMENTAL
Intervention: Carbon nanoparticles injected into thyroid gland (trial group)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no carbon nanoparticles)
Number of subjects: 86
Study: 23904282

Group type: EXPERIMENTAL
Intervention: Leptin administration
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Metreleptin administration
Number of subjects: 11
Study: 20215668

Group type: EXPERIMENTAL
Intervention: ENDOFLAS (Zinc Oxide Eugenol and Calcium hydroxide with Iodoform)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: METAPEX (Calcium hydroxide with Iodoform)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RC FILL (Zinc Oxide Eugenol with Iodoform)
Number of subjects: 0
Study: 18819901

Group type: EXPERIMENTAL
Intervention: Local mild hypothermia therapy (LMH group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Routine treatment (RT group)
Number of subjects: 52
Study: 16688429

Group type: EXPERIMENTAL
Intervention: Minimally invasive posterior approach
Number of subjects: 152

Group type: COMPARATOR
Intervention: Classic anterolateral approach
Number of subjects: 152
Study: 12707230

Group type: EXPERIMENTAL
Intervention: Transendocardial injections of autologous mononuclear bone marrow cells (15 injections of 0.2 cc)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Transendocardial injections of autologous mononuclear bone marrow cells
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (last 7 patients)
Number of subjects: 21
Study: 11310908

Group type: EXPERIMENTAL
Intervention: Propofol EDTA
Number of subjects: 122

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 122
Study: 2206005

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at a dose of 0.27 IU/kg (0.1 mg/kg) three times weekly for 6 months
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment continued for another 6 months after initial treatment
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Withdrawal of GH after 12 months of treatment
Number of subjects: 95
Study: 7449300

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30687503

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS) providing 600 kcal and 22 g protein a day
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Between-meal snacks providing 600 kcal and 22 g protein a day
Number of subjects: 34
Study: 27621045

Group type: EXPERIMENTAL
Intervention: Long-acting reversible contraceptives (LARCs)
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: Non-LARC prescription methods
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: Nonprescription methods/no method
Number of subjects: 987

Group type: COMPARATOR
Intervention: LARCs
Number of subjects: 987

Group type: COMPARATOR
Intervention: Weight perception
Number of subjects: 987
Study: 27052067

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/kg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Alfentanil (10 μg/kg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (Normal saline)
Number of subjects: 75
Study: 24583315

Group type: EXPERIMENTAL
Intervention: Exertion-induced muscle injury and MT (n=15)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: MT only (n=11)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Exertion-induced muscle injury only (n=10)
Number of subjects: 36
Study: 22180446

Group type: EXPERIMENTAL
Intervention: Two additional home physiotherapy visits of functional weight‐bearing exercises, functional task‐specific training
Number of subjects: 107

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Two additional home physiotherapy visits
Number of subjects: 107
Study: 21110174

Group type: EXPERIMENTAL
Intervention: Acupoint catgut-embedding therapy
Number of subjects: 65

Group type: COMPARATOR
Intervention: Fufuchun Capsule (control)
Number of subjects: 65
Study: 17425514

Group type: EXPERIMENTAL
Intervention: High-salt diet (200 mmol sodium daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-salt diet (20 mmol sodium daily)
Number of subjects: 0
Study: 16366197

Group type: EXPERIMENTAL
Intervention: Cold exposure at 12 degrees C for 180 minutes
Number of subjects: 0
Study: 12160582

Group type: EXPERIMENTAL
Intervention: Conventional external irradiation with agonist analogue of gonadotropin-releasing hormone
Number of subjects: 405

Group type: COMPARATOR
Intervention: Conventional external irradiation without agonist analogue of gonadotropin-releasing hormone
Number of subjects: 405
Study: 11776800

Group type: EXPERIMENTAL
Intervention: NP regimen (NVB + PDD)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: NI regimen (NVB + IFO)
Number of subjects: 48
Study: 7601292

Group type: EXPERIMENTAL
Intervention: Combined alpha- and beta-adrenoceptor blocking agent
Number of subjects: 27
Study: 2696207

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine solution infiltration anesthesia
Number of subjects: 40
Study: 7040495

Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31975288

Group type: EXPERIMENTAL
Intervention: Behavioural intervention to reduce sedentary behaviour (motivational interviewing, setting of behavioural goals)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Behavioural intervention to reduce sedentary behaviour
Number of subjects: 35

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 35
Study: 31404581

Group type: EXPERIMENTAL
Intervention: Bipolar transurethral enucleation and resection of the prostate (B‐TUERP)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Bipolar transurethral resection of the prostate (B‐TURP)
Number of subjects: 240
Study: 28245877

Group type: EXPERIMENTAL
Intervention: Performance-based financing (PBF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced financing (C1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pure control (C2)
Number of subjects: 0
Study: 26732187

Group type: EXPERIMENTAL
Intervention: Intensive nutritional education aimed at salt restriction to 6 g/d by nutritionists
Number of subjects: 95

Group type: COMPARATOR
Intervention: Conventional salt‐restriction education
Number of subjects: 95
Study: 25312265

Group type: EXPERIMENTAL
Intervention: Sufentanil (0.2 μg/kg, n = 24)
Number of subjects: 53
Study: 23316559

Group type: EXPERIMENTAL
Intervention: Closed approach with scaling/root planing (SRP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Closed approach with laser-curettage/SRP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Closed approach with laser-curettage/SRP/laser-sealing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open approach (papilla reflection/flap closure)
Number of subjects: 0
Study: 19430821

Group type: EXPERIMENTAL
Intervention: Variolink/Syntac Classic (VSC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: iCem (IC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Panavia F2.0 (PAF)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: RelyX Unicem (RLX)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Maxcem Elite (MCE)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Experimental self-adhesive resin cement (EXP)
Number of subjects: 60
Study: 18327605

Group type: EXPERIMENTAL
Intervention: BVS(On)
Number of subjects: 7
Study: 16339612

Group type: EXPERIMENTAL
Intervention: Any depression care
Number of subjects: 1175

Group type: EXPERIMENTAL
Intervention: Guideline-level depression care (antidepressant use or specialty counseling)
Number of subjects: 1175

Group type: COMPARATOR
Intervention: Clinic percentage of Latino patients
Number of subjects: 1175
Study: 12463661

Group type: EXPERIMENTAL
Intervention: Internal fixation
Number of subjects: 455

Group type: COMPARATOR
Intervention: Hemiarthroplasty
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 455
Study: 10726430

Group type: EXPERIMENTAL
Intervention: Predicted MLSS velocity (trial 1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.13 m sec-1 (4-8%) above predicted MLSS velocity (trial 2)
Number of subjects: 10
Study: 8835247

Group type: EXPERIMENTAL
Intervention: IgG glycosylation abnormalities in patients with RA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 2183112

Group type: EXPERIMENTAL
Intervention: gentamicin-clindamycin
Number of subjects: 130

Group type: COMPARATOR
Intervention: cefoxitin-doxycycline
Number of subjects: 130
Study: 6139668

Group type: EXPERIMENTAL
Intervention: Heat-inactivated hepatitis B vaccine (3 micrograms of surface antigen) given at 0, 1, 2, and 5 months
Number of subjects: 401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study: 31931932

Group type: EXPERIMENTAL
Intervention: Propranolol (0.5‐3 mg/Kg body weight per day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 31273908

Group type: EXPERIMENTAL
Intervention: Group-based diabetes prevention and management programme
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Individual change processes (information provision, structuring and prioritizing health goals, action planning, self-monitoring, receiving feedback)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Group processes (common purpose, sharing experiences, social comparisons, monitoring and accountability, social support)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Supportive group context (group cohesion, homogeneous group composition, positive group atmosphere)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Optimal facilitation methods
Number of subjects: 20
Study: 27765557

Group type: EXPERIMENTAL
Intervention: Talocrural mobilization with movement (MWM)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 26
Study: 26224232

Group type: EXPERIMENTAL
Intervention: Topical antioxidant cream
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 24479524

Group type: EXPERIMENTAL
Intervention: Chloroquine chemoprophylaxis and three intradermal doses of aseptic, purified Plasmodium falciparum sporozoites.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil (Malarone®) treatment initiated on day 11 post-CHMI.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Follow-up cardiac MRI at almost five months post-CHMI.
Number of subjects: 1
Study: 22939581

Group type: EXPERIMENTAL
Intervention: Undetected diabetics (HbA1c ≥6.5%)
Number of subjects: 626

Group type: COMPARATOR
Intervention: Nondiabetics (HbA1c <6.5%)
Number of subjects: 626

Group type: COMPARATOR
Intervention: Known diabetics (HbA1c ≥6.5%)
Number of subjects: 626
Study: 19716640

Group type: EXPERIMENTAL
Intervention: Mechanical active compression-decompression (ACD) CPR
Number of subjects: 126

Group type: COMPARATOR
Intervention: Manual CPR (Control)
Number of subjects: 126
Study: 17761579

Group type: EXPERIMENTAL
Intervention: Greater sitting height
Number of subjects: 10413

Group type: EXPERIMENTAL
Intervention: Longer legs
Number of subjects: 10413
Study: 15037054

Group type: EXPERIMENTAL
Intervention: Cued key press task with instructed probabilities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cued key press task with a posteriori probabilities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preparatory EEG negativity amplitudes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Overall task performance
Number of subjects: 0
Study: 11465647

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Verapamil (SR‐V)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 46
Study: 9762658

Group type: EXPERIMENTAL
Intervention: CSF-enriched antibodies
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Selected peptides
Number of subjects: 55
Study: 7999195

Group type: EXPERIMENTAL
Intervention: New Pathway curriculum
Number of subjects: 121

Group type: COMPARATOR
Intervention: Traditional curriculum
Number of subjects: 121
Study: 3397807

Group type: EXPERIMENTAL
Intervention: Combination met‐hGH plus oxandrolone
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Met‐hGH alone
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Met‐hGH
Number of subjects: 70
Study: 31883847

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with mucosal grass pollen allergen exposure
Number of subjects: 40
Study: 29238967

Group type: EXPERIMENTAL
Intervention: Anabasum 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anabasum 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 0
Study: 28931377

Group type: EXPERIMENTAL
Intervention: Physical therapy program augmented with mobile tele-health technology (6-10 total visits over 1 year)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Physical therapy program augmented with mobile tele-health technology
Number of subjects: 75

Group type: COMPARATOR
Intervention: Propensity score matched controls from the cohort study
Number of subjects: 75
Study: 26437721

Group type: EXPERIMENTAL
Intervention: Energy drink primes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Masculinity norms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distraction and placebo treatment
Number of subjects: 0
Study: 24159345

Group type: EXPERIMENTAL
Intervention: Standardized ethanol extract (1% and 2%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21555314

Group type: EXPERIMENTAL
Intervention: Jetstream atherectomy device
Number of subjects: 172
Study: 19058687

Group type: EXPERIMENTAL
Intervention: Polyacid modified resin composite (Dyract eXtra)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nanocomposite (Filtek Supreme)
Number of subjects: 24
Study: 15998356

Group type: EXPERIMENTAL
Intervention: 1.2 g chitosan twice daily for 3 months
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo twice daily for 3 months
Number of subjects: 130
Study: 12706712

Group type: EXPERIMENTAL
Intervention: Trivalent, intranasal, live attenuated influenza virus vaccine (LAIV)
Number of subjects: 4561